JP2007530703A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530703A5
JP2007530703A5 JP2007506442A JP2007506442A JP2007530703A5 JP 2007530703 A5 JP2007530703 A5 JP 2007530703A5 JP 2007506442 A JP2007506442 A JP 2007506442A JP 2007506442 A JP2007506442 A JP 2007506442A JP 2007530703 A5 JP2007530703 A5 JP 2007530703A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutical composition
disease
neuropathy
damaged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007506442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/010371 external-priority patent/WO2005097098A2/en
Publication of JP2007530703A publication Critical patent/JP2007530703A/ja
Publication of JP2007530703A5 publication Critical patent/JP2007530703A5/ja
Abandoned legal-status Critical Current

Links

JP2007506442A 2004-04-01 2005-03-29 Msおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用 Abandoned JP2007530703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
US60/558,533 2004-04-01
PCT/US2005/010371 WO2005097098A2 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Publications (2)

Publication Number Publication Date
JP2007530703A JP2007530703A (ja) 2007-11-01
JP2007530703A5 true JP2007530703A5 (https=) 2008-05-08

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506442A Abandoned JP2007530703A (ja) 2004-04-01 2005-03-29 Msおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用

Country Status (16)

Country Link
US (1) US20070149580A1 (https=)
EP (1) EP1737440A2 (https=)
JP (1) JP2007530703A (https=)
KR (1) KR20060134191A (https=)
CN (1) CN1950077A (https=)
AU (1) AU2005231358A1 (https=)
BR (1) BRPI0509540A (https=)
CA (1) CA2561159A1 (https=)
IL (1) IL178165A0 (https=)
MA (1) MA28561B1 (https=)
MX (1) MXPA06011218A (https=)
NO (1) NO20064985L (https=)
RU (1) RU2006138495A (https=)
SG (1) SG138623A1 (https=)
WO (1) WO2005097098A2 (https=)
ZA (1) ZA200607850B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EP1964575B1 (en) * 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8329725B2 (en) 2008-06-09 2012-12-11 Sanofi Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
KR20120107113A (ko) 2009-12-17 2012-09-28 사노피 수초 염기성 단백질 프로모터(mbp-luci)의 조절 하에 루시페라제를 발현하는 동물 모델 및 생물발광 생체내 영상화를 위한 상기 동물 모델의 용도
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
JPWO2004093910A1 (ja) * 2003-04-22 2006-07-13 アステラス製薬株式会社 PPARδアゴニストによる脳神経変性疾患治療剤

Similar Documents

Publication Publication Date Title
JP2007530703A5 (https=)
JP2018518537A5 (https=)
JP2007504174A5 (https=)
JP2011057693A5 (https=)
JP2020519661A5 (https=)
JP2012530779A5 (https=)
JP2014502641A5 (https=)
JP2014051526A5 (https=)
JP2007508361A5 (https=)
JP2019516739A5 (https=)
JP2013545730A5 (https=)
JP2009535352A5 (https=)
JP2013523893A5 (https=)
JP2009533356A5 (https=)
JP2006182786A5 (https=)
JP2006509749A5 (https=)
JP2015522547A5 (https=)
JP2008539268A5 (https=)
JP2009504748A5 (https=)
JP2010518061A5 (https=)
JP2011505356A5 (https=)
JP2007504235A5 (https=)
JP2016537338A5 (https=)
JP2013542981A5 (https=)
JP2008513510A5 (https=)